康希诺生物(06185):DTCP–HIb–MCV4联合疫苗启动I期临床试验并完成首例受试者入组

智通财经
Dec 19, 2025

智通财经APP讯,康希诺生物(06185)发布公告,公司研发的吸附无细胞百(组分)白破(DTcP)b型流感嗜血杆菌(结合)(Hib)-ACYW135群脑膜炎球菌(结合)(MCV4)联合疫苗(DTcP-Hib-MCV4联合疫苗)于近日正式启动I期临床试验,并完成首例受试者入组。

基于本公司的产品管线布局,结合市场对多联疫苗的需求,并形成差异化竞争,公司拟研发DTcP-Hib-MCV4联合疫苗。I期临床试验为评价DTcP-Hib-MCV4联合疫苗在2月龄至6岁人群中接种的安全性及免疫塬性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10